CLS receives second order from the National Institutes of Health Clinical Center in the US
Lund, Sweden April 9, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today announced that it has received its second order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System accessories.
The order of single-use sterile instruments includes introducers, temperature probes, and unique, non-cooled laser applicators that will be used to assess the clinical utility of CLS’s TRANBERG Thermal Therapy System towards MRI/Ultrasound fusion-guided focal laser ablation (FLA) of prostate tissue and prostate cancer in male patients.
The order falls under the research collaboration agreement between NIH and CLS that was launched in April last year.
Prostate cancer is one of the most common forms of cancer, and in the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
“This second order enables our continued research collaboration with NIH that evaluates our TRANBERG products for focal laser ablation to treat prostate cancer. The goal of the research collaboration and this study is to demonstrate that image-guided focal laser ablation is a safe and effective treatment option with the absence of the typical side effects often associated with radiation and surgical treatment,” says Dan J. Mogren, CEO, CLS.
About the National Institutes of Health (NIH)
NIH, the U.S. medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
For further information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company’s interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se